US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Lytix Biopharma – Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion

Oslo, November 21st 2024: Lytix Biopharma refers to the release made today by its licensing partner Verrica Pharmaceuticals, announcing the pricing of a USD 42 million underwritten public offering. The offering is expected to close on November 22, 2024, and the gross proceeds from the offering are expected to be approximately USD 42.0 million. Verrica also granted the underwriter an option for a period of 30 days to purchase up to 7,080,000 additional shares. The full announcement can be read via this link: https://verrica.com/press_release/verrica-announces-pricing-of-42-0-million-

Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization

Oslo, 19 November 2024. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, today releases its third quarter 2024 results. Lytix achieved substantial progress in its clinical pipeline, progressing towards commercialization.   “Our progress this quarter underscores Lytix’s potential to deliver transformative treatments for cancer patients,” said Øystein Rekdal, CEO of Lytix Biopharma. “The positive data from our ongoing studies, especially in basal cell carcinoma and melanoma, reinforce the

Lytix Biopharma: Invitation to Q3 2024 Results Presentation

Lytix Biopharma AS (Euronext Growth Oslo: LYTIX), a leading Norwegian immuno-oncology company, will release its third quarter 2024 financial results on Tuesday, 19 November 2024.   Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO Gjest Breistein, where they will discuss the results and provide key insights.   Date: Tuesday, 19 November 2024 Time: 10:30 AM CET   Q&A Session: We welcome your questions in advance. Please send them to post@lytixbiopharma.com, and they will be addressed during the Q&A session following the presentation.

First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma

Oslo, Norway, November 6, 2024 - Lytix Biopharma, a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, announces that the first patient has been treated in a new Phase II trial (NeoLIPA). The study evaluates the effect of Lytix’s lead drug candidate, LTX-315, in early-stage patients diagnosed with melanoma. Melanoma is the most severe type of skin cancer with a rising incidence globally and an estimated global market of USD 11 billion by 2030.   “By expanding our clinical trials to early-stage melanoma patients we are adding to our robust

Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals

Oslo, November 5th, 2024: Lytix Biopharma, a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, refers to the third quarter announcement made by its licensing partner Verrica Pharmaceuticals November 4th, 2024.   In the release, Verrica Pharmaceuticals reported financial results, provided an update on its strategies to strengthen the balance sheet and announced a new management.   Dr. Jayson Rieger is appointed as new CEO of Verrica Pharmaceuticals. Rieger is also a board member of Lytix Biopharma and will continue as part of the Board of

Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference

Oslo, Norway, October 24, 2024 - Lytix Biopharma, a Norwegian immuno-oncology company, today announces the acceptance of two abstracts showcasing positive preliminary topline results from Part 2 of the Phase II clinical study of LTX-315 (named VP-315 by Lytix’s licensing partner Verrica Pharmaceuticals) for the treatment of basal cell carcinoma (BCC). BCC is the largest skin cancer disease globally with a projected global market size of USD 11.5 bn in 2028 and 3.6 million new cases in the US annually[1].  Presentations of study abstracts and posters are important milestones as it’s a

Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization

Oslo, 29 August 2024. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, today releases its second quarter and first half 2024 results. Lytix Biopharma is experiencing a pivotal shift for its lead drug candidates, marked by significant clinical progress.   Results from the Phase II study in patients with the skin cancer disease basal cell carcinoma (BCC) demonstrate that Lytix's lead drug candidate, LTX-315, achieved an 86% reduction in tumor size and complete elimination in over half of

Lytix Biopharma: Invitation to Q2 2024 Results Presentation

Lytix Biopharma AS (Euronext Growth Oslo: LYTIX), a leading Norwegian immuno-oncology company, will release its second quarter 2024 financial results on Thursday, 29 August 2024. Date: Thursday, 29 August 2024Time: 10:00 AM CET Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO Gjest Breistein, where they will discuss the results and provide key insights. Q&A Session:We welcome your questions in advance. Please send them to post@lytixbiopharma.com, and they will be addressed during the Q&A session following the presentation. Webcast Details:The

PhII preliminary results from skin cancer clinical trial show an 86%overall reduction of tumor size, complete clearance in 51%of the patients and the potential to be utilized as a first-line therapy

Oslo, 14 August 2024. Lytix Biopharma (“Lytix”) announces that its Nasdaq-listed licensing partner Verrica Pharmaceuticals reports positive top-line Phase II results from its study in patients with basal cell carcinoma (BCC) - the largest skin cancer disease globally with a projected global market size of USD 11.5 bn in 2028 (CAGR 7.9%) and 3.6 million new cases in the US annually [1].    The study investigates Lytix’s lead drug candidate LTX-315 in BCC patients and shows impressively an: · 86 percent overall reduction of tumor size · 51 percent complete clearance rate of

Lytix Biopharma: Lytix’s licensing partner, Verrica Pharmaceuticals, to release preliminary topline results from their Phase II trial of LTX-315 for the treatment of basal cell carcinoma on August 14

Oslo, August 06, 2024. Lytix Biopharma announces that its licensing partner, Verrica Pharmaceuticals, will host an investor call to report preliminary top-line data of its phase II study in patients with the skin cancer disease basal cell carcinoma on Wednesday, August 14 at 14:30 CET (included in Verrica’s presentation of its second quarter financial results). In this phase II study, Lytix’s lead drug candidate LTX-315 (named VP-315 in Verrica’s study) has been tested in basal cell carcinoma patients. BCC is the most common type of cancer worldwide, with 3-4 million annual incidents in

Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones

Oslo, 30 May 2024. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, today releases its first quarter 2024 results.   During the quarter, the company reached important clinical progress in two Phase II studies investigating its lead cancer drug candidate for two different types of skin cancer. Lytix`s licensing partner Verrica Pharmaceuticals achieved a complete patient enrollment in its Phase II study in basal cell carcinoma. Furthermore, Lytix achieved positive interim results from its

Lytix Biopharma: Invitation to presentation of first quarter 2024 results, Thursday 30 May 2024

Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, will release its first quarter 2024 results on Thursday, 30 May 2024. The results will be presented in a webcast with CEO Øystein Rekdal and CFO Gjest Breistein at 1:00pm CET.   We encourage you to send us questions in advance, to be addressed during the Q&A session. Please send your questions in an email to post@lytixbiopharma.com.   The presentation and subsequent Q&A session will be held in English and may be viewed live by registering here: https://forms.office.com/e/0djcLzR8Za

Lytix Biopharma – Minutes of Ordinary General Meeting

Oslo, Norway, May 14, 2024 – The Ordinary General Meeting of Lytix Biopharma AS ("Lytix" or the "Company") was held on May 14, 2024. All proposed resolutions on the agenda were approved.   Minutes of the meeting are attached hereto.   The minutes and all documents relevant for the annual general meeting are available on the Company's website.   For more information, please contact: Gjest Breistein, CFO +47 952 60 512 gjest.breistein@lytixbiopharma.com   About Lytix Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly

Lytix Biopharma AS - New share capital registered

Oslo, Norway, 13 May 2024: Reference is made to the stock exchange announcements published by Lytix Biopharma AS ("Lytix" or the "Company") on 25 April 2024 and 26 April 2024 regarding the issuance of a total of 9,541,984 shares (the "Offer Shares") by the Company's extraordinary general meeting and the board of directors pursuant to a board authorization relating to a partially guaranteed share offering (the "Offering"). The share capital increases relating to the Offering have today been registered with the Norwegian Register of Business Enterprises. The Company's new share capital is

Correction in the notice of Annual General Meeting in Lytix Biopharma AS

Oslo, 3 May 2024: Reference is made to the stock exchange announcement published on 30 April 2024 where Lytix Biopharma AS (the "Company") published a notice of the Annual General Meeting to be held on 14 May 2024 at 13:00 (CEST) (the "Notice").   In the Notice, the "Record Date" for shareholders who can attend and vote at the Annual General Meeting was set to 9 May 2024. The correct "Record Date" is 6 May 2024.     No other revisions have been made to the Notice or its appendices.   For further information, please see the Company’s website or contact CFO Gjest Breistein.

Lytix Biopharma AS: Notice of Annual General Meeting on 14 May 2024

Oslo, 30 April 2024, the Board of Directors hereby calls for the Annual General Meeting of Lytix Biopharma AS (the "Company") in Sandakerveien 130, 0484 Oslo, Norway at 13:00 Hours (CEST) on 14 May 2024.   All documents regarding the Annual General Meeting are available at the Company's website: www.lytixbiopharma.com.   For further information, please see the Company’s website or contact CFO Gjest Breistein. Please see below for contact details.   Gjest Breistein, CFO E-mail: gjest.breistein@lytixbiopharma.com Phone: +47 952 60 512   About Lytix Based in

Lytix Biopharma AS: Annual Report for 2023

Oslo, Norway, April 30, 2024 – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that it has published its Annual Report for 2023, which was approved by the board of directors on April 29, 2024.   “In 2023, our unique position in the immune-oncology field has been strengthened with positive interim results from two phase II studies. Our oncolytic molecules have the potential to solve one of the major challenges in current cancer therapy: tumor heterogeneity”, says Øystein Rekdal, CEO of Lytix Biopharma.   The Annual

Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates

Oslo, Norway, 26 April 2024: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or the "Company") earlier today, on 26 April 2024, regarding a share issue of 486,377 shares (the "Offer Shares") pursuant to a board autorisation granted by the Company's extraordinary general meeting on 25 April 2024.   As of this date, the Company has been informed that the following close associates to primary insiders have been allocated Offer Shares, as set out below:   Hifo Invest AS, a close associate to primary insider, Brynjar Forbergsskog,

Lytix Biopharma AS – Share issue pursuant to board authorisation

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, Norway, 26 April 2024: Reference is made to the stock exchange announcements published by Lytix Biopharma AS ("Lytix" or the "Company") on 25 April 2024 regarding the minutes of the extraordinary general meeting held on 25 April

Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates

Oslo, Norway, 25 April 2024: Reference is made to the stock exchange announcements published by Lytix Biopharma AS ("Lytix" or the "Company") earlier today, on 25 April 2024, regarding the final results of the partially guaranteed share offering (the "Offering").   As of this date, the Company has been informed that the following primary insiders and close associates to primary insiders have been allocated new shares in the Offering, as set out below:   Hifo Invest AS, a close associate to primary insider, Brynjar Forbergsskog, subscribed for 724,448.00 shares in the Offering.

Lytix Biopharma AS – Minutes of extraordinary general meeting and final results of share offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, Norway, 25 April 2024: Reference is made to the stock exchange announcements published by Lytix Biopharma AS ("Lytix" or the "Company") on 24 April 2024, regarding the results of a partially guaranteed share offering (the "

Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity

Oslo, 25 April 2024. Lytix Biopharma announces that the Norwegian Medical Products Agency has approved the clinical trial application for a Phase II Neoadjuvant study in early-stage melanoma, a severe form of skin cancer. In this study, Lytix`s lead candidate LTX-315 will be given in combination with another type of immunotherapy before surgery. The study is called NeoLIPA and will be led by Dr. Henrik Jespersen, Head of Melanoma Oncology at Radiumhospitalet (Oslo University Hospital).   “We are very excited to start the NeoLIPA study and investigate the clinical effect of LTX-315 in

Lytix Biopharma AS – Preliminary results in the share offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, Norway, 24 April 2024: Reference is made to the stock exchange announcements published by Lytix Biopharma AS ("Lytix" or the "Company") on 9 and 10 April 2024, regarding the launch of a partially guaranteed share offering (the "

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe